Spyre Therapeutics, Inc. (SYRE) Stock Overview
Explore Spyre Therapeutics, Inc.’s financial performance, market position, analyst ratings, and future outlook.
Spyre Therapeutics, Inc. (SYRE)
Key Financials
Key Financials
Market Cap
6.2B
P/E Ratio
-46.39
EPS (TTM)
$-2.08
ROE
-0.31%
SYRE Stock Analysis & Investment Overview (NASDAQ)
Our AI-powered analysis of Spyre Therapeutics, Inc. (NASDAQ: SYRE) gives investors deep insight into how the stock performs on the NASDAQ exchange, its growth potential, and its market positioning. With a Meyka AI Score of B, Spyre Therapeutics, Inc.'s NASDAQ-listed shares demonstrate moderate investment characteristics based on our machine learning models.
The current technical analysis of SYRE on the NASDAQ shows an RSI of 59.01, suggesting the stock is in a a neutral condition. Our forecasting models predict a 12-month price target of $50.09 for the NASDAQ listing.
Key metrics behind Spyre Therapeutics, Inc.'s NASDAQ-traded stock include a P/E ratio of -46.39 and a market capitalization of 6.2B. Combined with our AI analysis, these give both institutional and retail investors a clear view of SYRE on the NASDAQ.